

**Supplementary figure 7**. (A) Illustration of cytokines secreted by PSCs. (B) Sphere formation capacity of PANC-1 cells cultured in PSC-CM derived serum-free medium after blocking with series of cytokine antibodies, respectively. Anti-IL6, anti-IL8, anti-GRO, anti-CSF2, anti-MCP1, anti-PDGF, anti-CXCL12, anti-activin-A, anti-CTGF, anti-periostin and anti-endothelin antibodies were used. IgG isotype were used as control. (C) The actual sphere number (left) and the fold change of sphere number (right) in PANC-1-vector/EHF after culturing with PSC-CM derived serum-free medium neutralized with anti-IL6 antibody. (D) The actual sphere number (left) and the fold change of sphere number (right) in PANC-1-vector/EHF after culturing with PSC-CM derived serum-free medium neutralized with anti-IL8 antibody. (E) The actual sphere number (left) and the fold change of sphere medium neutralized with anti-IL8 antibody. (E) The actual sphere number (left) and the fold change of sphere medium neutralized with anti-IL8 antibody. (E) The actual sphere number (left) and the fold change of sphere medium neutralized with anti-IL8 antibody. (E) The actual sphere number (left) and the fold change of sphere medium neutralized with anti-IL8 antibody. (E) The actual sphere number (left) and the fold change of sphere number (right) in PANC-1-vector/EHF after culturing with PSC-CM derived serum-free medium neutralized with anti-IL8 antibody. (E) The actual sphere number (left) and the fold change of sphere number (right) in PANC-1-vector/EHF after culturing with PSC-CM derived serum-free medium neutralized with anti-CXCL12 antibody. \**P*<0.05, \*\**P*<0.01 and n.s. means non-significant.